Quality by Design in Drug Product Development
A risk-based approach from start of development until submission

SPEAKERS:

Dr Michael Braun
Boehringer Ingelheim Pharma, Germany

Dr Andrea Staab
Boehringer Ingelheim Pharma, Germany

Dr Jobst Limberg
Federal Institute for Drugs and Medical Devices, BfArM, Germany

Dr Gerald Kindermann
F. Hoffmann-La Roche, Switzerland

10-11 October 2017, Heidelberg, Germany

HIGHLIGHTS:

- Application of QbD during different stages of drug product development
- Regulatory perspective
- Knowledge management
- Risk management and control strategy
- Reports and documentation
- Examples and case studies on DoE, PAT and statistic approaches
- Two hours of interactive workshops

This education course is recognised for the ECA GMP Certification Programme „Certified Pharmaceutical Development Manager“. Please find details at www.gmp-certification.eu
Quality by Design in Drug Product Development
10-11 October 2017, Heidelberg, Germany

Objectives
The aim of this two-day course is to provide practical guidance on how QbD principles can be translated and implemented in drug product development. This course will deal among others with the following questions:

- What are the opportunities and challenges of applying QbD to drug product development?
- What are the current status and future expectations of QbD (ICH, FDA, EMA)?
- How can Quality Target Product Profile (QTPP) and concepts of life cycle management (ICH Q12) increase regulatory flexibility?
- What are the regulatory expectations in view of terminology and QbD related content of module 3?
- How to perform focused risk assessments for efficient development work?
- Why is it important to have a clear understanding and expectation of process performance?
- What is the impact of QbD on drug product development, scale-up and transfer?
- How can QbD also benefit marketed products?

Interactive workshops will enable delegates to apply what they have learned and to discuss the concepts in more detail. Delegates will have the opportunity to work through the whole QbD process by gaining “hands-on experience” from a number of examples and case studies.

Background
The pharmaceutical industry is currently embracing QbD concepts to help improve the robustness of manufacturing processes and to facilitate continuous improvement strategies to enhance product quality and availability throughout a product’s life cycle. QbD ensures product quality and requires process performance characteristics to be scientifically designed to meet specific objectives, not merely empirically derived from the performance of test batches. Key QbD concepts are described in ICH guidelines Q8 Pharmaceutical Development, Q9 Quality Risk Management and Q10 Pharmaceutical Quality System. A new ICH guideline Q12 on Life cycle Management, which is intended to complement existing ICH Q8 to Q11 guidelines, is planned.

Risk- and science-based product development requires the support of structured tools for experimental planning and knowledge management. The documentation of the development work in risk assessments and development reports is a key to efficient compilation of the submission dossier.

Process Analytical Technology (PAT) is a key tool to an effective implementation of QbD as a way to achieve process knowledge and control. Through application of PAT during development and advanced monitoring and control options, process performance can be improved.

Initiatives from regulatory authorities like the recently published draft Annex 17 (EU GMP Guideline) on “Real Time Release Testing” emphasize the advances in the application of PAT, QbD and quality risk management (QRM) principles to pharmaceutical development and manufacturing (including quality control).

Target Audience
This course aims to provide a potential way how to meet current regulatory expectations and realize the Process Design Stage in practice. Special focus is set on the application of an alternate risk assessment approach as a guiding tool that drives drug product development. Another important aspect is adequate reporting and documentation of results that are finally summarized in the submission dossier.

This course is designed for drug product managers and scientists who are responsible for performing or reviewing activities like drug product development, process validation, scale-up and transfer, and CMC dossier preparation.

In addition, QA and regulatory affairs professionals will benefit from this course by gaining an understanding of current CMC trends. This will aid more effective multifunctional discussions on these topics within industry.

Programme

Introduction to drug product development - setting the scene
- Drug product development at a glance – from first in man to marketing authorization
- Pharmaceutical QbD: Quo vadis?
- Application of QbD principles to drug product development

Expectations from regulatory agencies
- Regulatory initiatives and approaches for supporting emerging technologies
- Concepts of Real Time Release Testing (Draft Annex 17 EU GMP Guideline)
- Harmonization of regulatory requirements (QbD parallel-assessment FDA-EMA, ICH Q8 -> Draft Q12?)
- Regulatory expectations: Lessons learned from applications so far

Knowledge Management
- Knowledge Management (KM) System - Definition and Reason
- Knowledge Management Cycle
- Explicit and Tacit Knowledge - The Knowledge Spiral
- Correlation between KM and other Processes
- Enabling Knowledge Management
- Knowledge Review - integral part of the Management Review (ICH Q10)
Quality Risk Assessment and Control Strategy
- Objectives of Quality Risk Assessment (QRA) as part of development
- Overview to risk assessment tools
- Introduction of Process Risk Map
- Introduction of risk based control strategy development

QbD Toolbox: Case studies DoE, PAT, and Basic Statistics
- Value-added use of QbD tools – generic approaches and tailored solutions
- Case studies and examples for different unit operations and variable problems

Workshop Process Risk Map & link to Control Strategy
Based on a risk assessment tool tailored to cover development needs, delegates will work on case studies of process development for a solid oral dosage form.
- From QTPP and CQA to relationship analysis of process parameters and material attributes
- Process mapping for integrated documentation of the development work
- Process Risk Map as a tool for development-focused risk assessment

Reports and Documentation
- Development Reports
- Transfer protocols and reports
- Control Strategy and link to the submission dossier

Wrap-up & Final Discussion
The concepts and tools used over the two days will be summarized and future implications and opportunities of applying QbD principles to process development will be discussed. Delegates will be given time to ask questions on how they can apply what they have learned to their own drug product development and manufacturing.

Speakers

Dr Michael Braun, Boehringer Ingelheim Pharma GmbH, Germany
Dr Braun is a trained pharmacist with more than 15 years of experience in Drug Product Development. He received his Ph.D. in Pharmaceutical Technology at the University of Bonn and started his career in pharmaceutical industry as Head of Pharmaceutical Development at Rentschler Pharma. In 2006 Michael joined Boehringer Ingelheim and worked in different positions with increasing responsibility within Pharmaceutical Development and R&D Project Management. Since 2014, he is Director Late Stage Drug Product Development and responsible for process development and scale-up of solid and liquid orals, parenterals and inhalative NCE products. This also includes product transfers to operations, launch support and preparation of submission documentation.

Dr Gerald Kindermann, F. Hoffmann-La Roche, Switzerland
Dr Kindermann joined Roche in 1996. From 2001 to 2003 he led the group for the control of incoming packaging materials where he was responsible for release analysis of packaging materials and the technical control of all packaging materials. After that he was responsible for packaging materials as Quality Manager. In 2008 he joined the Global Quality group at Roche, currently working as Head Network Support, focusing on project management.

Dr Jobst Limberg, Federal Institute for Drugs and Medical Devices, BfArM, Germany
Dr Limberg joined BfArM in 1990. From 1995 to 2005 he was head of the unit “Pharmaceutical Technology”. Following an interdisciplinary reorganization in 2005, he was appointed head of regulatory unit “Cardiology”. Starting 2012 he is head of section “Scientific Quality” in the department European and International Affairs. He is responsible for scientific coordination of pharmaceutical quality in the German Drug Regulatory Agency and is the nominated German member of the Quality Working Party of the European Medicines Agency (EMA). He is also involved in the national PAT group and the respective international groups at EMA in London and EDQM in Strasbourg.

Dr Andrea Staab, Boehringer Ingelheim Pharma GmbH, Germany
After obtaining her PhD degree in Pharmaceutical Technology from the University of Regensburg, Dr Andrea Staab worked in different functions within Pharmaceutical Development at Aventis (2001-2005) and Boehringer Ingelheim (since 2005), covering drug product development work from early formulation to late stage process development. Since 2012, she is head of Process Science and Quality by Design Support within Late Stage Drug Product Development at Boehringer Ingelheim. Her responsibilities cover the documentation of the drug product development strategy and development work from risk-based experimental planning to submission for marketing authorization.
Reservation Form

**Reservation Form:**

**CONCEPT HEIDELBERG**
P.O. Box 10 17 64
69007 Heidelberg
Germany

**Reservation Form:**

+49 6221 84 44 34

**@ e-mail:**

info@concept-heidelberg.de

**Internet:**

www.gmp-compliance.org

**Date**

Tuesday, 10 October 2017, 9.00 h – 17.00 h
(Registration and coffee 8.30 h – 9.00 h)
Wednesday, 11 October 2017, 8.30 h – 13.30 h

**Venue**

Heidelberg Marriott Hotel
Vangerowstrasse 16
69115 Heidelberg, Germany
Phone +49 (0) 6221 – 908 0 | Fax +49 (0) 6221 – 908 698
email info.heidelberg@marriott.com

**Fees (per delegate plus VAT)**

- ECA Members € 1,490
- APIC Members € 1,590
- Non-ECA Members € 1,690
- EU GMP Inspectorates € 845

The conference fee is payable in advance after receipt of invoice and includes conference documentation, lunch and dinner on the first day, business lunch on second day and all refreshments. VAT is reclaimable.

**Would you like to save money?**

If you book “QbD in Drug Product Development” AND “QbD in API Manufacturing” simultaneously, the fee for EACH conference reduces as follows:

- ECA Members € 1,290
- APIC Members € 1,390
- Non-ECA Members € 1,490
- EU GMP Inspectorates € 745

**Accommodation**

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

**Registration**

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

**Social Event**

In the evening of the first course day, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

**Conference Language**

The official conference language will be English.

**Organisation and Contact**

CONCEPT HEIDELBERG, P.O. Box 10 17 64
69007 Heidelberg, Germany
Phone +49-62 21/84 44-0, Fax +49-62 21/84 44 84
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content:
Dr Andrea Kühn-Hebecker (Operations Director)
at +49-62 21/84 44 35, or per e-mail at kuehn@concept-heidelberg.de

For questions regarding reservation, hotel, organisation etc.:
Mr Niklaus Thiel (Organisation Manager)
at +49-62 21/84 44 43, or per e-mail at thiel@concept-heidelberg.de

**General terms and conditions**

- If the bill-to-address deviates from the specifications on the right, please fill out here:

**Privacy Policy:**
By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the purposes of informing me about similar events and for the publication of the event. You have the right to withdraw your consent at any time. Your data will not be passed on to third parties. Further information can be obtained from the privacy policy at www.gmp-compliance.org.

wa/vorl/20120207